Moderna Shares Surge Over 50% in Pre-Market Trading as Company and Merck Announce Melanoma Skin Cancer Vaccine Met Primary Endpoint in Large-Scale Trial

Wallstreetcn
2026.08.19 10:58

Moderna shares rose more than 50% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine met its primary endpoint in a large-scale trial. Risk Warning and Disclaimer: The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investors bear full responsibility for their own investment decisions

Moderna shares surged over 50% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine met its primary endpoint in a large-scale trial.

Risk Warning and Disclaimer

The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investors bear full responsibility for their own investment decisions.

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.